Antigenics exchanges shares for $1.27 million 5.25% convertibles

By Devika Patel

Knoxville, Tenn., Sept. 11 - Antigenics Inc. agreed to issue 424,330 common shares in exchange for $1.27 million of its 5.25% convertible senior notes due February 2025 on Sept. 9, according to an 8-K filed Friday with the Securities and Exchange Commission.

Antigenics is a New York-based biotechnology company with a focus on cancers and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.